CAPR News and Press, Capricor Therapeutics Inc. From 05/20/24

2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...

2024-05-17 10:09:23 ET Capricor Therapeutics ( NASDAQ: CAPR ) has been initiated at Outperform by Oppenheimer on hopes of positive outcome from the company’s Phase 3 trial of its Duchenne muscular dystrophy treatment.... Read the full article on Seeking Alpha For ...

2024-05-17 10:00:30 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

2024-05-16 17:15:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for CAPR on May 16, 2024 04:05PM ET. CAPR was trading at $5.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommend...

2024-05-14 03:03:07 ET Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript May 13, 2024, 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Ted Tenthoff...

2024-05-13 16:13:33 ET More on Capricor Therapeutics Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript Capricor Therapeutics Q1 2024 Earnings Preview Capricor scales up manufacturing capacity for DMD therapy Seeking Alpha’s Quant Rati...

–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Maj...

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...

-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024- SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechno...